Celltrion

As a global biopharmaceutical company, Celltrion has pioneered the biosimilar industry and continues to lead the global biologics market. Building on this success, we are expanding into next-generation therapeutics that are shaping the future of healthcare. Our growing R&D pipeline includes novel antibodies, antibody-drug conjugates (ADCs), multispecific antibodies, and microbiome-based therapies—laying the foundation for long-term, sustainable growth.

At the heart of this innovation is our people. Approximately 30% of our workforce is dedicated to R&D, with a high proportion holding advanced degrees (Master’s and Ph.D.). This strong talent base enables us to drive complex, high-impact research and maintain scientific excellence. Through close collaboration across specialized teams, we remain agile in a rapidly evolving biopharmaceutical landscape.

▲ Global R&D Center Researchers

Strategy ① Antibody-Drug Conjugates (ADCs)
ADCs are advanced therapies that link monoclonal antibodies with cytotoxic agents, such as anticancer drugs to deliver targeted treatment directly to diseased cells, minimizing harm to healthy tissue. This precision approach is gaining momentum, especially in oncology.
Celltrion is actively expanding its ADC pipeline through in-house development and global partnerships. Our first candidate, CT-P70, has been submitted for IND approval, and two additional programs are advancing toward clinical entry.

Strategy ② Multispecific Antibodies
Multispecific antibodies are engineered to bind two or more distinct antigens simultaneously, offering enhanced therapeutic potential compared to traditional monoclonal antibodies. They are especially promising in the treatment of solid tumors. In particular, by applying Celltrion's antibody therapeutics R&D technology and production platform, high synergy effects can be expected. Through a dual-track strategy of internal development and external licensing, Celltrion is rapidly building a competitive pipeline in this emerging field.

Strategy ③ Microbiome-Based Therapeutics
Microbiome therapies leverage beneficial microorganisms to treat a wide range of conditions, including cancers, autoimmune diseases, and neurological disorders. Celltrion is accelerating development in this area through global collaborations. We are co-developing candidates for irritable bowel syndrome, atopic dermatitis, and Parkinson’s disease, and preparing investigator-initiated clinical trials for treatments targeting multidrug-resistant infections.

▲ Next Generation R&D Growth Strategy

Celltrion remains committed to advancing innovation beyond biosimilars. By investing in novel biologics and next-generation technologies, we aim to deliver transformative therapies that improve patient outcomes and set new standards in global healthcare.